Release Date: April 25, 2024
Expiration Date: October 18, 2025
Activity Overview
This online activity is designed to update clinicians on data presented at meetings including Hawaiian Eye and Retina, held January 13-19, 2024 in Wailea, Hawaii, and Angiogenesis, Exudation, and Degeneration, held virtually on February 3, 2024. Expert thought leaders provide insights to help clinicians apply these findings to their management of patients with nAMD and DME when using newer therapies that support longer treatment intervals.
Target Audience
This educational activity is directed toward retina specialists, general ophthalmologists, and general optometrists.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize emerging evidence regarding the management of retinal diseases as presented at major medical conferences in 2024
- Identify appropriate patient populations who may benefit from evidence-based therapies used in the management of nAMD based on clinical presentation and goals of treatment
- Identify appropriate patient populations who may benefit from evidence-based therapies used in the management of DME based on clinical presentation and goals of treatment
- Integrate evidence regarding advanced dosing strategies into individualized management plans for patients with DME
W. Lloyd Clark, MD
Assistant Clinical Professor of Ophthalmology
University of South Carolina School of Medicine
Palmetto Retina Center
Columbia, SC
Disclosures: Consultant: Amgen, Cardinal Health, Genentech/Roche, Kodiak Sciences, Regeneron. Speaker: Genentech/Roche, Regeneron. Grants: Genentech/Roche, Regeneron.
Roger A. Goldberg, MD, MBA
Vitreoretinal Specialist
Partner, Bay Area Retina Associates, Walnut Creek, CA
Faculty, CPMC Ophthalmology, San Francisco, CA
Disclosures: Research Grants: AffaMed, Allergan, Annexon, Apellis, Boehringer Ingelheim, EyePoint, Genentech, Janssen, Neurotech, Novo Nordisk, Unity, ZEISS; Consultant: Allergan, Annexon, Apellis, Boehringer Ingelheim, Biogen, Coherus, EyePoint, Genentech, IrisVision, Ocular Therapeutix, Outlook, Regeneron, ZEISS; Speaker: Apellis, Biogen, Genentech; Stock Owner: Emmetrope Ophthalmics.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here